| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
|
J Clin Oncol
|
2006
|
2.79
|
|
2
|
A novel method of 18F radiolabeling for PET.
|
J Nucl Med
|
2009
|
2.35
|
|
3
|
Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study.
|
J Urol
|
2010
|
2.17
|
|
4
|
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
|
Blood
|
2013
|
1.78
|
|
5
|
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
|
J Nucl Med
|
2006
|
1.77
|
|
6
|
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex.
|
Bioconjug Chem
|
2010
|
1.76
|
|
7
|
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
|
Nat Med
|
2005
|
1.69
|
|
8
|
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
|
Blood
|
2012
|
1.63
|
|
9
|
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.
|
Blood
|
2010
|
1.53
|
|
10
|
CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
|
Clin Cancer Res
|
2007
|
1.51
|
|
11
|
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.
|
Proc Natl Acad Sci U S A
|
2006
|
1.50
|
|
12
|
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
|
Clin Cancer Res
|
2005
|
1.49
|
|
13
|
Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting.
|
J Nucl Med
|
2007
|
1.35
|
|
14
|
Pretargeted molecular imaging and radioimmunotherapy.
|
Theranostics
|
2012
|
1.31
|
|
15
|
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
|
Blood
|
2008
|
1.30
|
|
16
|
Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
|
J Nucl Med
|
2006
|
1.18
|
|
17
|
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
|
Cancer Res
|
2008
|
1.15
|
|
18
|
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
|
Mol Cancer Ther
|
2010
|
1.13
|
|
19
|
Efficacy of an alpha1 blocker in expulsive therapy of lower ureteral stones.
|
J Endourol
|
2008
|
1.11
|
|
20
|
Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study.
|
Urol Res
|
2009
|
1.10
|
|
21
|
Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.
|
Clin Cancer Res
|
2005
|
1.09
|
|
22
|
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
|
Cancer Res
|
2008
|
1.08
|
|
23
|
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
|
Cancer Res
|
2008
|
1.07
|
|
24
|
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
|
Radiology
|
2008
|
1.04
|
|
25
|
Effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study.
|
Urol Int
|
2009
|
1.02
|
|
26
|
Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?
|
Eur J Nucl Med Mol Imaging
|
2003
|
0.99
|
|
27
|
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.
|
Blood
|
2009
|
0.99
|
|
28
|
Doppler ultrasound-guided percutaneous nephrolithotomy: a prospective randomized study.
|
Urology
|
2011
|
0.98
|
|
29
|
Pretargeting: taking an alternate route for localizing radionuclides.
|
Tumour Biol
|
2012
|
0.97
|
|
30
|
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
|
Semin Nucl Med
|
2010
|
0.96
|
|
31
|
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
|
Blood
|
2009
|
0.96
|
|
32
|
Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo.
|
Int J Cancer
|
2011
|
0.95
|
|
33
|
Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
|
J Nucl Med
|
2009
|
0.95
|
|
34
|
Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
|
J Nucl Med
|
2004
|
0.93
|
|
35
|
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
|
J Nucl Med
|
2009
|
0.93
|
|
36
|
Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy.
|
Clin Cancer Res
|
2003
|
0.93
|
|
37
|
Complex and defined biostructures with the dock-and-lock method.
|
Trends Pharmacol Sci
|
2012
|
0.93
|
|
38
|
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
|
Blood
|
2007
|
0.93
|
|
39
|
Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
|
Clin Cancer Res
|
2004
|
0.90
|
|
40
|
Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
|
Clin Cancer Res
|
2006
|
0.89
|
|
41
|
Indications of stented uncomplicated ureteroscopic lithotripsy: a prospective randomized controlled study.
|
Urol Res
|
2009
|
0.89
|
|
42
|
A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers.
|
J Nucl Med
|
2012
|
0.89
|
|
43
|
Adjunctive medical therapy with an alpha-1A-specific blocker after shock wave lithotripsy of lower ureteral stones.
|
Urol Int
|
2009
|
0.88
|
|
44
|
Development of humanized antibodies as cancer therapeutics.
|
Methods
|
2005
|
0.88
|
|
45
|
A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.
|
Cancer Res
|
2010
|
0.88
|
|
46
|
Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro.
|
BMC Cancer
|
2013
|
0.87
|
|
47
|
Novel strategies for improved cancer vaccines.
|
Expert Rev Vaccines
|
2009
|
0.87
|
|
48
|
Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology.
|
PLoS One
|
2013
|
0.87
|
|
49
|
Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells.
|
Clin Cancer Res
|
2005
|
0.87
|
|
50
|
Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
|
Eur J Nucl Med Mol Imaging
|
2005
|
0.86
|
|
51
|
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties.
|
Bioconjug Chem
|
2012
|
0.85
|
|
52
|
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.
|
Blood
|
2010
|
0.85
|
|
53
|
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells.
|
PLoS One
|
2013
|
0.85
|
|
54
|
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
|
J Nucl Med
|
2012
|
0.85
|
|
55
|
Randomized trial of NTrap for proximal ureteral stones.
|
Urology
|
2011
|
0.85
|
|
56
|
The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures.
|
Bioconjug Chem
|
2012
|
0.84
|
|
57
|
Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update.
|
Clin Cancer Res
|
2007
|
0.84
|
|
58
|
Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.
|
Blood
|
2011
|
0.84
|
|
59
|
A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines.
|
Biotechnol Prog
|
2011
|
0.83
|
|
60
|
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.83
|
|
61
|
Simultaneous bilateral tubeless percutaneous nephrolithotomy of staghorn stones: a prospective randomized controlled study.
|
Urol Res
|
2010
|
0.82
|
|
62
|
Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody.
|
Cancer
|
2010
|
0.82
|
|
63
|
Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
|
Biol Blood Marrow Transplant
|
2012
|
0.80
|
|
64
|
Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer.
|
J Nucl Med
|
2012
|
0.80
|
|
65
|
Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method.
|
EJNMMI Res
|
2012
|
0.78
|
|
66
|
Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.
|
Mol Cancer
|
2014
|
0.78
|
|
67
|
Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga.
|
J Nucl Med
|
2011
|
0.78
|
|
68
|
Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.
|
Cancer Biother Radiopharm
|
2010
|
0.77
|
|
69
|
A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies.
|
Clin Cancer Res
|
2007
|
0.77
|